Since its inception in 2010, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna has established relationships with government and commercial collaborators, which have allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. In Canada, Moderna has a 10-year strategic partnership with the Canadian government to enhance pandemic response capabilities, which includes building an advanced mRNA manufacturing facility for respiratory vaccines currently under construction in Quebec. Moderna is also committed to helping position Canada as a leader in mRNA research and development with partnerships across the country. To learn more, visit www.modernatx.com/en-CA